OMAR Opioid Use Disorder
Study Details
Study Description
Brief Summary
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Detailed Description
The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand [11C] OMAR, in healthy individuals and individuals diagnosed with opioid use disorder. Research participants may complete screening, MRI, PET scan and follow up visits.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Healthy Volunteers Healthy volunteers with no current or past major medical or psychiatric history |
Drug: [11C]OMAR
For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered.
Other Names:
|
Opioid Use Disorder Patients diagnosed with opioid use disorder |
Drug: [11C]OMAR
For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- CB1R Availability [One time within 4 weeks of screening]
To compare cortical CB1R availability in individuals diagnosed with opioid use disorder on chronic methadone maintenance vs. matched healthy controls.
Secondary Outcome Measures
- Serum Endocannabinoid Levels [One time within 4 weeks of screening]
To explore group differences in serum endocannabinoid levels in individuals diagnosed with opioid use disorder on chronic methadone maintenance vs. matched healthy controls.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Able to provide informed consent
-
Male and female 18-55 years old (inclusive)
-
DSM-5 diagnosis of opioid use disorder (for OUD group)
-
Physically healthy i.e., no clinically unstable medical conditions
-
Written informed consent and have capacity to consent and comply with study procedures
Exclusion Criteria:
-
Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).
-
Presence of ferromagnetic metal in the body or heart pacemaker
-
Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
-
Are claustrophobic
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Yale University
- National Institute on Drug Abuse (NIDA)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2000033525